Venomics AI raises $2.7M to hunt for drugs in animal venoms

Who backed Venomics AI

Speciale Invest and South Park Commons co-led the $2.7 million pre-seed round for Bengaluru startup Venomics AI, with Operators Studio also investing.

How the funds will be spent

Venomics AI plans to spend the $2.7 million on two fronts. First, it will bulk up Venom Atlas, its database of venom-derived molecules. Second, it will refine the AI models that rank promising candidates and upgrade the lab gear that screens them.

The startup begins with molecular sequencing of snake, scorpion and marine-animal venoms. Its algorithms then flag the most promising molecules, and automated lab tests validate their drug-like properties. Each result feeds back into the AI, steadily improving accuracy.

How Venomics AI started—and where it stands now

Venomics AI emerged from the Indian Institute of Science in May 2026, founded by venom biologist Kartik Sunagar and data scientist Vinay Prabhu. Sunagar calls animal venoms a "rich yet underexplored" source of new medicines.

The fledgling company has already built the core of its platform. It also joined NVIDIA’s Inception programme for AI startups and landed a spot as a Top-5 finalist for the 2026 Indo-Boston Biotech Bridge Award.

India’s biotech sector heats up

India’s bioeconomy is racing toward $300 billion by 2030, according to the India Brand Equity Foundation. Investors are piling in: Cellogen Therapeutics recently raised ₹20 crore from Kotak Alternate Asset Managers, while StrainX Bioworks secured $13 million in a round led by Prime Venture Partners and Leo Capital.

The government is amplifying the push. In the 2027 Budget, Finance Minister Nirmala Sitharaman unveiled ‘Biopharma SHAKTI’, a ₹10,000 crore scheme to accelerate biotech innovation.

Bengaluru remains a hub. Peptris Technologies, another AI-driven drug-discovery startup in the city, closed a ₹70 crore Series A round earlier this year.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Venomics AI’s narrow focus on venom molecules gives it a clear edge in India’s crowded AI drug-discovery market. The funding shows investors value startups that combine deep biology with machine learning—and the backing of South Park Commons confirms the technology itself is sound.

Key takeaways

• The $2.7 million pre-seed will speed up construction of the Venom Atlas and expand lab capacity.
• By concentrating on venom-derived compounds, Venomics stands out from generic AI drug-discovery platforms.
• The government’s ₹10,000 Cr ‘Biopharma SHAKTI’ scheme may soon offer additional non-dilutive capital.
• Rivals like Snaayu Lifesciences and Peptris Technologies are also attracting funding, signaling strong investor appetite.

Related on Lazyfounder

• South Park Commons
• Prime Venture Partners
• More startup news